Source link : https://www.newshealth.biz/health-news/time-to-revisit-off-label-comt-use/
PHILADELPHIA — Early adjuvant use of opicapone (Ongentys) may reduce the risk for complications in patients with early Parkinson’s disease (PD) and no motor complications. The US Food and Drug Administration approved opicapone, a once-daily peripheral catechol-O-methyltransferase (COMT) inhibitor, in 2020 as add-on therapy to reduce “off” periods in patients with PD on a stable […]
Author : News Health
Publish date : 2024-10-11 11:44:54
Copyright for syndicated content belongs to the linked Source.